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Abstract
Objective: To identify features of the gut microbiome associated with multiple
sclerosis activity over time. Methods: We used 16S ribosomal RNA sequencing
from stool of 55 recently diagnosed pediatric-onset multiple sclerosis patients.
Microbiome features included the abundance of individual microbes and net-
works identified from weighted genetic correlation network analyses. Prentice-
Williams-Peterson Cox proportional hazards models estimated the associations
between features and three disease activity outcomes: clinical relapses and both
new/enlarging T2 lesions and new gadolinium-enhancing lesions on brain MRI.
Analyses were adjusted for age, sex, and disease-modifying therapies. Results:
Participants were followed, on average, 2.1 years. Five microbes were nominally
associated with all three disease activity outcomes after multiple testing correc-
tion. These included butyrate producers Odoribacter (relapse hazard
ratio = 0.46, 95% confidence interval: 0.24, 0.88) and Butyricicoccus (relapse
hazard ratio = 0.49, 95% confidence interval: 0.28, 0.88). Two networks of co-
occurring gut microbes were significantly associated with a higher hazard of
both MRI outcomes (gadolinium-enhancing lesion hazard ratios (95% confi-
dence intervals) for Modules 32 and 33 were 1.29 (1.08, 1.54) and 1.42 (1.18,
1.71), respectively; T2 lesion hazard ratios (95% confidence intervals) for Mod-
ules 32 and 33 were 1.34 (1.15, 1.56) and 1.41 (1.21, 1.64), respectively).
Metagenomic predictions of these networks demonstrated enrichment for
amino acid biosynthesis pathways. Interpretation: Both individual and net-
works of gut microbes were associated with longitudinal multiple sclerosis
activity. Known functions and metagenomic predictions of these microbes
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suggest the important role of butyrate and amino acid biosynthesis pathways.
This provides strong support for future development of personalized micro-
biome interventions to modify multiple sclerosis disease activity.
Introduction
Multiple sclerosis (MS) is a chronic, inflammatory disease
of the central nervous system with symptoms and disease
activity that vary greatly from person to person. Despite
recent advances in treatment, there is no cure for MS,
and it remains largely unknown what factors contribute
to disease activity over time. Smoking, obesity, Epstein–
Barr virus infection, low vitamin D, and over 200 genetic
variants are established risk factors for developing MS.
However, with the exception of low vitamin D, they have
not been convincingly or consistently shown to contribute
to MS outcomes such as clinical relapse or lesion activity
on brain MRI.1,2 Thus, it is critical to investigate the
novel drivers of MS activity that might inform interven-
tions designed to attenuate disease course.
Recently, a growing body of experimental and observa-
tional studies have suggested that microbes in the gut
contribute to MS pathogenesis.3 Several potential biologi-
cal mechanisms include direct and indirect interactions of
microbes and microbial metabolites with immune cells
and pro-inflammatory chemokines and cytokines, all of
which can influence the central nervous system.4–6 How-
ever, it remains unknown which, if any, features of the
gut microbiome contribute to disease activity in MS. In
animal models of MS, a germ-free environment has been
associated with lower disease activity, and perturbations
to the gut microbiota have been associated with changes
in disease activity.7–9 Additionally, the oral administration
of Bacteroides fragilis has been associated with lower “clin-
ical” scores in relapsing mouse models of MS.10 One
small observational study of the gut microbiome and dis-
ease activity in persons with MS investigated clinical
relapse as the outcome.11 After adjusting for age and
disease-modifying therapy (DMT) use, the relative
absence of Fusobacteria was associated with a higher
chance of relapse (hazard ratio = 3.2; 95% confidence
interval: 1.2, 9.0). This study was limited in size, did not
investigate the role of specific microbial taxa (such as
genus or species) or co-occurring networks of microbes,
and did not include other clinical outcomes. No studies
have investigated the association between gut microbes
and direct measures of disease activity assessed by brain
MRI, which is sensitive to lesion formation, more com-
mon than clinical relapses,12 and can serve as a biomarker
of active inflammation.
In this study, we utilized 16S ribosomal RNA sequenc-
ing profiles from the stool of 55 pediatric-onset MS cases
to investigate whether specific features of the gut micro-
biome were associated with time to three separate disease
activity outcomes: clinical relapses, new gadolinium-
enhancing lesions (representing areas of active inflamma-
tion), and new or enlarging T2-hyperintense lesions
(markers of overall disease burden). Using pediatric-onset
cases (individuals with MS symptom onset before
18 years of age) to investigate these associations was
advantageous, because symptom onset was likely closer to
the biological onset of disease. Further, children and
youth have higher disease activity, compared to adults,




Between 2012 and 2018, 60 individuals with MS onset
before 18 years old were enrolled and provided stool sam-
ples that could be analyzed. Six enrollees did not have
clinical follow-up (leaving 54 in the “clinical cohort”) and
14 did not have subsequent MRI scan data available (leav-
ing 46 in the “MRI cohort”). Participants were recruited
from seven sites in the US Network of Pediatric MS Cen-
ters including the University of California San Francisco,
State University of New York at Buffalo, University of
Alabama at Birmingham, Boston Children’s Hospital,
Stony Brook University Medical Center, Children’s
Hospital of Philadelphia, and New York University. At
stool sample collection (“baseline”), all participants were
within 24 months of symptom onset and met the 2010
McDonald criteria for MS.15 Exclusion criteria included:
participant’s banked serum tested positive for myelin
oligodendrocyte glycoprotein antibodies, participant had
been exposed to a systemic antibiotic, probiotic, or ster-
oid within 1 month prior to stool sample collection, or
participant had previously used a cytotoxic immunosup-
pressant.
All parents and participants provided written informed
consent and assent. Ethical approval for the study was
obtained from each institution’s Institutional Review
Board.
Clinical relapses and MRI outcomes
During the study period, participants were seen for regu-
lar care at the enrolling clinic, which usually included a
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visit every 6 months, with additional visits if the partici-
pant experienced a relapse or other clinical reason. MRI
scans were ordered at study visits (per the primary neu-
rologist) and conducted using each site’s scanner and
local protocol. Data from follow-up visits (including the
dates of relapse onset, use of DMTs, and MRI) were
prospectively entered into a web-based registry. The Data
Coordinating and Analysis Center at the University of
Utah managed the data and performed quality control.
Three outcomes, which could recur over the study per-
iod, were assessed separately: clinical relapse(s), develop-
ment of new gadolinium-enhancing brain lesion(s), and
development of new or enlarging T2 hyperintense brain
lesion(s). These outcomes were defined previously.16 We
considered a lesion new or enlarging relative to the previ-
ous MRI.
Gut microbiota profiling
A parent collected the participant’s first stool of the day
and shipped overnight on ice to the University of Califor-
nia, San Francisco, where it was stored at 80°C before
processing. DNA was extracted, and the V4 region of the
16S rRNA gene was amplified for sequencing, as previ-
ously described.17
Forward and reverse reads were processed separately,
and quality filtered using the DADA2 package version
1.9.0. in R.3.5.2.18,19 Reads having more than two
expected errors or ≤150 base pairs in length were
removed. Error rates of the filtered dereplicated reads
were estimated using 100,000 sequences. Paired sequenc-
ing reads with a minimum overlap of 25 base pairs were
merged to obtain the full denoised sequences. Chimeras
and any sequences abnormally short or long were
removed. Amplicon sequence variants (ASVs) were
inferred exactly, resolving variants that differ by as little
as one nucleotide. Taxonomy was assigned using the
na€ıve Bayesian classifier method (Kingdom to Family)
and exact string matching (Genus and Species) utilizing
the SILVA v132 reference database.18,20,21 It is important
to note that while an ASV has a unique nucleotide
sequence, it might not be assigned a unique species or
taxonomy due to limitations of 16S sequencing in deter-
mining strain-level differences among species and missing
microbial genomes in reference databases. Using the de-
contam package, ASVs with a contaminant classification
threshold p < 0.1 were removed.22 ASVs containing less
than 1/1000th of a percent of total reads were removed.
Sequencing reads were representatively rarefied to the
minimum sequencing depth (84,818 reads/sample) 100
times, and the rarefied sample profile closest to the
sample-specific centroid was selected, as described previ-
ously.17 The resulting tables included 1,482 ASVs.
Covariates
Upon enrollment, participants completed a questionnaire
including age, symptom onset, race, ethnicity, and sex.
Medication history was obtained, and subsequent medica-
tion use was tracked over the follow-up period. Disease-
modifying therapies included those previously described.16
For relapse-related analyses, time-varying DMT use was
defined as “yes” if the subject used a DMT within
3 months prior to the respective relapse, and “no” if
otherwise. For MRI analyses, time-varying DMT use was
defined as “yes” if the subject was using a DMT during
the period between the respective MRI and the previous
MRI and “no” if otherwise.
Statistical analyses
Alpha and beta diversity
All statistical analyses were completed using R and the
phyloseq package.23 Alpha (within sample) diversity was
evaluated using a rarefied ASV table with richness (Chao1
and Faith’s phylogenetic diversity) and evenness (Pielou)
estimators. To test for the association between each alpha
diversity metric and time to each disease activity out-
come, we used Prentice-Williams-Petersen time-to-event
models.24 These are an extension of Cox proportional
hazard models and are appropriate for outcomes that can
recur over the study period and are not independent.
For relapse analyses, clinical cohort members were fol-
lowed from baseline to the earlier of the final clinic visit
or occurrence of a third relapse (Fig. 1 panel A). Relapses
were truncated after the first three to prevent the estima-
tion of hazard ratios (HRs) in event strata with few indi-
viduals. Time to each relapse (or final clinic visit) was
defined as the total time from baseline to each respective
event. Because, by definition, a new relapse cannot occur
until at least 30 days after the previous relapse, a 30-day
period was discounted from the follow-up time at risk for
each subsequent relapse.
For brain MRI analyses, MRI cohort members were fol-
lowed from baseline to the earlier of the final MRI or
occurrence of a second new/enlarging lesion (gadolinium-
enhancing and T2 lesions were evaluated separately)
(Fig. 1 panel B). Data were truncated after the first two
new/enlarging lesions. Since a new or enlarging lesion was
relative to a past MRI, we defined a “baseline MRI” as
the MRI that occurred closest, but previously, to stool
sample collection. Time to each new/enlarging lesion (or
final MRI visit) was defined as the gap time between a
new/enlarging lesion and the previous new/enlarging
lesion (or baseline if first new/enlarging lesion). We used
the midpoint of time between a MRI with a new/enlarg-
ing lesion and prior MRI (with or without new/enlarging
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lesion) as an estimate of when the new lesion devel-
oped.16,25 Between baseline and a new/enlarging lesion,
the midpoint was halfway between the baseline MRI and
the new/enlarging lesion, and time between stool collec-
tion and the midpoint was used for the respective at-risk
interval. If the midpoint between the baseline MRI and
first MRI with a new/enlarging lesion after baseline
occurred before stool was collected, it was excluded from
analyses.
For all Prentice-Williams-Petersen models, robust vari-
ance was computed, and HRs and 95% confidence inter-
vals (CIs) were estimated for each alpha diversity metric
and each MS activity outcome, adjusting for sex, age at
event, and DMT use. The proportional hazard assump-
tion for each model was assessed using the cox.zph func-
tion in the Survival package. All alpha diversity metrics
met the proportional hazard assumption.
For beta (between sample) diversity, weighted and
unweighted UniFrac distance matrices were constructed.26
Relationships between each beta diversity metric and
whether a participant had a clinically meaningful relapse
rate (annual rate ≥0.5, i.e., more than one relapse over
2 years), had any new gadolinium-enhancing lesions, or
had any new or enlarging T2 hyperintense lesions over
the follow-up period were assessed using permutational
multivariate analysis of variance (PERMANOVA) using
adonis2. Models were adjusted for sex, age at stool collec-
tion, and whether a participant was using a DMT when
stool was collected.
ASV-level relative abundance
To identify whether specific gut microbes were associated
with subsequent disease activity, we used Prentice-
Williams-Petersen models described above to estimate
HRs and 95% CIs for each ASV and each disease activity
outcome, adjusted for age, sex, and DMT use. ASVs iden-
tified in <20% of a respective analytic cohort (clinical or
MRI) were excluded to reduce potentially spurious taxa
and reduce the burden of multiple testing with a small
sample. Rarefied counts of each ASV were dichotomized
according to prevalence. ASVs in 20% to <80% of sam-
ples were categorized as “present” or “absent” if any or
no taxa reads were in the sample. ASVs in ≥80% of sam-
ples were categorized as “high” or “low” depending on
whether samples had ≥ or < the median number of taxa
reads. This resulted in 271 ASVs available for individual-
level analyses for the clinical cohort and 256 ASVs for the
MRI cohort. For each disease activity outcome, observa-
tions were corrected for false discovery rate (FDR) using
the Benjamini–Hochberg method.27 ASVs with FDR q-
value<0.05 were considered significant.27 The proportional
hazard assumption for significant ASVs was assessed the
same as above, and all met the proportional hazard
assumption.
Microbial network analysis
The co-occurrence networks of ASVs in at least 10% of
samples (resulting in 437 ASVs available for the clinical
Figure 1. Example of survival analyses for relapse and MRI outcomes. (A) For relapse analyses, time to each relapse (an “event” in panel A)
started on the day stool was collected (d0) and ended on the day of each respective relapse or the last study visit where relapse status was
known (dx). A 30-day period was subtracted from the at-risk period following a relapse because, by definition, a new relapse must be at least
30 days after the previous. (B) For MRI analyses, an “event” was defined as a brain MRI that indicated a new or enlarging lesion compared to the
prior MRI. Specifically, we used two MRI outcomes considered separately: new gadolinium-enhancing lesion and new or enlarging T2 lesion.
Because the timing of MRI varies in clinical practice and the specific time of lesion activity is unknown, midpoint survival analyses were used. For
the first MRI event after stool was collected, time at risk started on the date stool was collected and ended on the midpoint between the first
MRI event and the prior MRI where an event did not occur (or the MRI that preceded baseline). For subsequent MRI events, time at risk started
on the date of the previous MRI with an event and ended on the midpoint between the respective MRI event and the prior MRI where an event
did or did not occur. Individuals were censored at the date of their last MRI (with or without an MRI event) before the study end.
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cohort and 426 for the MRI cohort) were constructed
from an unrarefied ASV table using SPIEC-EASI and
WGCNA packages.28,29 A correlation matrix was gener-
ated using SPIEC-EASI, transformed to an adjacency
matrix using soft thresholding, and a topology overlap
matrix was generated. The topology overlap matrix was
hierarchically clustered using hclust, and the resulting
dendrogram was cut using dynamicTreeCut in the stats
package to generate modules (clusters). Modules needing
at least three ASVs to be retained. Correlated modules
(r ≥ 0.5) were combined, generating a dissimilarity matrix
for further hierarchical clustering. The quantitative values
of each module were calculated for each participant from
module eigengenes, defined as the first principal compo-
nent of the abundance matrix of a respective module.
Each module eigengene was tested for its association with
time to relapse, new gadolinium-enhancing lesions, and
new or enlarging T2 hyperintense lesions using the
Prentice-Williams-Petersen models described above,
adjusting for age, sex, and DMT use. To improve the
interpretability of results, we presented beta coefficients
and HRs from regression coefficients and 95% CIs scaled
to a 0.1-unit increase in module eigengenes. Analyses
were corrected for FDR, and modules with an FDR q-
value<0.05 were considered significant. The proportional
hazard assumption for significant ASVs was assessed the
same as above. One significant module did not meet the
proportional hazard assumption, so a time by eigengene
interaction term was added to the model. The interaction
term did not have p < 0.05, so the HR and 95% CI for
the module eigengene from the noninteraction term
model were presented.
Metagenomic prediction
Conserved functional genes of microbes within each sig-
nificant module were predicted using PICRUSt 2.30 For
each significant module, predicted gene counts were
grouped into MetaCyc metabolic pathways.31 We esti-
mated the association between predicted metabolic path-
ways in at least 20% of samples and the disease activity
outcome(s) previously identified as associated with the
respective module. Pathway abundances were dichoto-
mized as > or ≤ the respective pathway’s median abun-
dance. HRs and 95% CIs were estimated using Prentice-
Williams-Petersen models, adjusted for age, sex, and
disease-modifying use, and corrected for FDR.
Data availability
The data that support the findings of this study are avail-
able on request from the corresponding author.
Results
Characteristics of pediatric-onset multiple
sclerosis microbiome cohort
Among all 55 cohort members, the average age at baseline
was 15.9 years (IQR = 2.5), 72.7% were female, 67.2%
identified as white, and 36.3% identified as Hispanic
(Table 1). The distribution of these characteristics match
the sex, age, race, and ethnicity distribution of pediatric-
onset MS in the United States.32 Approximately half were
using a DMT at baseline, of which 25.0% were using
interferon beta and 64.3% were using glatiramer acetate.
The proportion of individual’s ASVs belonging to a par-
ticular taxonomic class did not significantly differ by
baseline DMT use categories (none, glatiramer acetate,
interferon beta, or other DMT), except for Melainabacte-
ria (p = 0.0002) and Verrucomicrobiae (p = 0.049) (data
not shown, Supplementary Fig. S1). Among all 55 partici-
pants, 54 were prospectively followed and evaluated for
the presence (or absence) of clinical relapses (“clinical
cohort”) and 46 had at least one MRI scan available
(“MRI cohort”).
The characteristics of these cohorts were similar, albeit
a higher proportion of girls were in the clinical cohort
relative to MRI cohort (Table 1). For the relapse analyses,
participants were followed for an average of 2.4 years
(IQR = 2.1) after baseline during which time 44.4% expe-
rienced a relapse. Of the relapses that occurred, 75.5%
were using a DMT in the 3 months prior. Participants
were followed for a similar amount of time for the
gadolinium-enhancing (mean = 2.0 years, IQR = 1.7) and
T2 hyperintense lesion (mean = 1.9 years, IQR = 15)
analyses. Over the follow-up period, approximately half
of participants had a new or enlarging T2 hyperintense
lesion (54.3%) while 40.0% had a new gadolinium-
enhancing lesion.
Gut microbiome alpha and beta diversities
were not associated with multiple sclerosis
activity
Alpha diversity was not significantly associated with
relapse (pchao1 = 0.56, pfaith = 0.29, pevenness = 0.67), new
gadolinium-enhancing lesions (pchao1 = 0.16, pfaith = 0.15,
pevenness = 0.58), or new or enlarging T2 hyperintense
lesions (pchao1 = 0.84, pfaith = 0.77, pevenness = 0.95)
(Fig. 2). For beta diversity, relapse and MRI outcomes
did not explain the observed variance in microbiota com-
position in fecal samples (Fig. 3). Over the study period,
irrespective of whether a weighted or unweighted UniFrac
distance matrix was employed, variance in fecal micro-
biota composition was not related to MS activity
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outcomes: annualized relapse rate ≥0.5 (weighted UniFrac
PERMANOVA R2 = 0.01, p = 0.78; unweighted UniFrac
PERMANOVA R2 = 0.02, p = 0.38), having any new
gadolinium-enhancing lesions (weighted UniFrac
PERMANOVA R2 = 0.01, p = 0.78; unweighted UniFrac
PERMANOVA R2 = 0.02, p = 0.42), or having any new
T2 hyperintense lesions (weighted UniFrac
PERMANOVA R2 = 0.02, p = 0.43; unweighted UniFrac
PERMANOVA R2 = 0.02, = 0.63).
Five gut microbes were nominally
associated with all three multiple sclerosis
activity outcomes
A lack of relationship between MS activity and variance
in overall fecal microbiota composition does not pre-
clude the possibility that specific microbes may con-
tribute to MS pathogenesis. For this reason, we tested
whether specific ASVs were associated with pediatric-
onset MS outcomes. No ASVs were significantly associ-
ated with disease activity outcomes using a conservative
Table 1. Cohort characteristics of pediatric-onset multiple sclerosis








N (%) 55 (100.0) 54 (98.2) 46 (83.6)
Age (mean, IQR) 15.9 (2.5) 15.9 (2.5) 15.8 (2.6)
Age at disease onset,
years (mean, IQR)
14.7 (2.7) 14.7 (2.8) 14.6 (2.7)
Sex (female) (n, %) 40 (72.7) 39 (72.2) 33 (89.2)
Race (n, %)
Asian 4 (7.3) 4 (7.41) 3 (6.52)
Black 6 (10.9) 6 (11.1) 6 (13.0)
White 37 (67.2) 36 (66.7) 32 (69.6)
Other 6 (10.9) 6 (11.1) 5 (10.9)
Not reported 2 (3.6) 2 (3.7) 0 (0.0)








28 (50.9) 28 (51.9) 24 (52.2)
Interferon beta (n,
%)
7 (25.0) 7 (25.0) 6 (25.0)
Glatiramer acetate
(n, %)
18 (64.3) 18 (64.3) 16 (66.7)
Over follow-up period


















90 days prior (n, %)
37 (75.5)
Over follow-up period



















































and prior MRI (n,
%)
33 (97.1)
Abbreviations: DMT, disease-modifying therapy; IQR, interquartile
range.
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Figure 2. Microbial alpha diversity was not associated with clinical relapses or MRI outcomes in pediatric-onset multiple sclerosis. (A) The Chao1
microbial richness estimator was not associated with relapse (HR = 1.00; 95% CI: 0.99, 1.00; p = 0.56), new gadolinium-enhancing lesion on
MRI (HR = 0.99; 95% CI: 0.99, 1.00; p = 0.16), or new or enlarging T2 hyperintense lesion on MRI (HR = 1.00; 95% CI: 0.99, 1.01; p = 0.84).
(B) The Faith’s phylogenetic diversity microbial richness estimator was not associated with relapse (HR = 0.98; 95% CI: 0.94, 1.02; p = 0.29), new
gadolinium-enhancing lesion on MRI (HR = 0.96; 95% CI: 0.92, 1.01; p = 0.15), or new or enlarging T2 hyperintense lesion on MRI (HR = 0.99;
95% CI: 0.94, 1.04; p = 0.77). (C) Microbial evenness (Pielou estimator) was not associated with relapse (HR = 1.35; 95% CI: 0.34, 5.32;
p = 0.67), new gadolinium-enhancing lesions on MRI (HR = 0.64; 95% CI: 0.13, 3.08; p = 0.58), or new or enlarging T2 hyperintense lesions on
MRI (HR = 0.95; 95% CI: 0.19, 4.84; p = 0.95). Beta coefficients and related HRs and 95% CIs for evenness were scaled to represent a 0.1-unit
change in evenness. Regression models adjusted for sex, age, and disease-modifying therapy use.
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Figure 3. Variance in fecal microbiota composition was not associated with pediatric-onset multiple sclerosis clinical relapse and MRI outcomes.
Having, on average, more than 0.5 relapses per year was not associated with beta diversity using (A) weighted UniFrac
(PERMANOVA R2 = 0.01, p = 0.78) or (B) unweighted UniFrac distance matrices (PERMANOVA R2 = 0.02, p = 0.38). Having any new
gadolinium-enhancing lesions over the study period was not associated with beta diversity using (C) weighted UniFrac
(PERMANOVA R2 = 0.01, p = 0.78) or (D) unweighted UniFrac distance matrices (PERMANOVA R2 = 0.02, p = 0.42). Having any new or
enlarging T2 hyperintense lesions over the study period was not associated with beta diversity using (E) weighted UniFrac
(PERMANOVA R2 = 0.02, p = 0.43) or (F) unweighted UniFrac distance matrices (PERMANOVA R2 = 0.02, p = 0.63). PERMANOVA models
adjusted for sex, age, and disease-modifying therapy use. The first two principal coordinates from principal coordinate analysis were plotted.
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threshold of FDR q < 0.05 (Fig. 4, see Supplementary
Table S1 for full results). Using a less stringent cutoff of
FDR q < 0.2, we identified three ASVs associated with
disease activity. Two of these were associated with higher
hazard of relapse: Blautia stercoris (HR: 3.19, 95% CI:
1.72, 5.92) and an unidentified species within the genus
Catabacter (HR: 2.81, 95% CI: 1.51, 5.22). One ASV was
associated with a lower hazard of new gadolinium-
enhancing lesions, Odoribacter splanchnicus (HR: 0.25,
95% CI: 0.12, 0.54).
To explore whether there may be microbes associated
with all three disease activity outcomes, we compared the
effect sizes of ASVs across all three outcomes if the ASV
was associated with at least one outcome at p < 0.05.
While several ASVs were not tested in both the relapse
and MRI analyses because they were not in at least 20%
of both samples, we identified five ASVs associated with
all three disease activity outcomes (Fig. 5). Four of these
showed protective effects across all outcomes, meaning
having any of the respective ASV (or above the median
number of reads) was associated with a lower hazard of
relapses, gadolinium-enhancing lesions, and T2 hyperin-
tense lesions. These included Butyricicoccus desmolans
(HRrelapse = 0.49, 95% CI: 0.28, 0.88), Odoribacter
splanchnicus (HRrelapse = 0.46, 95% CI: 0.24, 0.88), an
unidentified species in the Lachnospiraceae NK4A136
group (HRrelapse = 0.47, 95% CI: 0.24, 0.89), and
Ruminococcaceae (HRrelapse = 0.45, 95% CI: 0.22, 0.91).
For these ASVs, similar HRs were observed for MRI out-
comes (Fig. 5 and Supplementary Table S1). In contrast,
having any reads of SV_520, an unspecified member of
Coriobacteriales was associated with more than double the
hazard for all three disease activity outcomes (HRre-
lapse = 2.25, 95% CI: 1.12, 4.49; HRGad = 3.36, 95% CI: 1.54,
7.35; HRT2 = 2.60, 95% CI: 1.34, 5.08). The abundance of
each of these five ASVs did not significantly differ by
baseline DMT status (data not shown).
Gut microbial networks were associated
with MRI outcomes
Gut microbes exist in complex, interconnected communi-
ties, so we tested the association between networks of co-
occurring microbes and each disease activity outcome.
Gut microbes were classified into 33 (M1-33) and 27
(M34-60) modules (or clusters/networks) using the MRI
and clinical cohorts, respectively (Supplementary Fig. S2).
The ASVs constituting each module for MRI and clinical
cohorts were shown in Supplementary Tables S2 and S3.
Among the 33 modules identified from subjects within
the MRI cohort, five (M7, 10, 11, 32, and 33) were signif-
icantly associated (FDR q < 0.05) with new gadolinium-
enhancing lesions (Fig. 6). Two of these modules were
protective, where higher module values were associated
with a lower hazard of new gadolinium-enhancing lesions:
M7 (HR = 0.37, 95% CI: 0.18, 0.76) and M10
(HR = 0.20, 95% CI: 0.06, 0.63). For the other three sig-
nificant modules, higher module values were associated
with a higher hazard of new gadolinium-enhancing
lesions: M11 (HR = 1.26, 95% CI: 1.12,1.42), M32
(HR = 1.29, 95% CI: 1.08, 1.54), and M33 (HR = 1.42,
95% CI: 1.18, 1.71). Higher M32 and M33 module values
were also significantly associated with higher hazard of
new or enlarging T2 hyperintense lesions (HRM32 = 1.34,
95% CI: 1.15 1.56; HRM33 = 1.41, 95% CI: 1.21, 1.64).
No other modules were significantly associated with new
or enlarging T2 hyperintense lesions, and no modules
were significantly associated with relapse(s) (see Supple-
mentary Tables S4 and S5 for full results). Interestingly,
only one of the five ASVs shown to be individually asso-
ciated with all three disease activity outcomes was a mem-
ber of a significant module. This was SV_245, an
unidentified member of the Lachnospiraceae NK4A136
group (which showed a protective effect for all three dis-
ease activity outcomes) and a member of the M10 mod-
ule (associated with a lower hazard for the MRI
outcomes).
Several of the modules significantly associated with
MRI outcomes could be mapped to the clinical modules.
Notably, all four ASVs within the significant M33 MRI
module were in the M56 clinical module. While not sta-
tistically significant, the effect size between the M56 mod-
ule and relapse (HRrelapse = 1.15, 95% CI: 0.98, 1.35) was
similar to the effect sizes between the M33 module and
MRI outcomes (HRGad = 1.42 and HRT2 = 1.40). Addi-
tionally, ASVs in the significant M32 MRI module over-
lapped with the M38 clinical module. The effect size
between the M38 module and relapse (HRrelapse = 1.21,
95% CI: 0.96, 1.53) was similar to the effect sizes between
the M32 module and MRI outcomes (HRGad = 1.29 and
HRT2 = 1.34).
Predicted functional pathways from gut
microbial networks were associated with
multiple sclerosis
Metabolic pathways identified in each significant fecal
microbial module were shown in Supplementary
Tables S6-S10. No modules were significantly associated
with relapse, so pathway–relapse associations were not
assessed. Metagenomic predictions indicated that modules
significantly associated with MRI outcomes encoded
amino acid biosynthesis pathways, including the super-
pathways of L-arginine and L-tryptophan biosynthesis
(Supplementary Tables S6-S10). Filtering pathways to
those only associated with an outcome at p < 0.05, several
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Figure 5. Five gut microbes were associated with all three pediatric-onset multiple sclerosis activity outcomes. Each row was an ASV that was
associated with either relapse, new gadolinium-enhancing lesions, or new or enlarging T2 hyperintense lesions at p < 0.05. Hazard ratios,
adjusted for sex, age, and disease-modifying therapy use, were shown for each significant (p < 0.05) ASV-outcome association. Gray indicated an
ASV–outcome association was not significant. “NA” indicated an association was not estimated because the ASV was not in at least 20% of the
respective sample. Rows were labeled with ASV ID and the lowest known taxonomic classification. Rows were arranged by taxonomic order.
Figure 4. No species of gut microbes were significantly (FDR q < 0.05) associated with pediatric-onset multiple sclerosis activity outcomes. The
long-dashed line indicated an FDR q cutoff of 0.05 and the small dotted line indicated a less conservative threshold FDR q = 0.2. Each point was
an ASV. The genus and species (or lowest known taxonomy) of ASVs associated with a respective outcome with FDR q < 0.2 were labeled.
Regression models were adjusted for sex, age, and disease-modifying therapy use. (A) Adjusted log-hazard ratios for relapse; (B) adjusted log-
hazard ratios for new gadolinium-enhancing lesions on MRI; and (C) adjusted log-hazard ratios for new or enlarging T2 hyperintense lesions on
MRI.
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pathways were specific to modules associated with a lower
hazard (M10 module) or higher hazard (M32 and M33
modules) for the MRI outcomes (Supplementary Fig. S3).
Notably, the superpathways of L-tyrosine (p = 0.01) and
L-phenylalanine (p = 0.01) biosynthesis were associated
with a lower hazard of MRI outcomes.
Discussion
In this longitudinal study of subjects with pediatric-onset
MS, we identified several individual gut microbes and
networks of co-occurring microbes associated with a
higher or lower hazard of clinical relapse and MRI-related
disease activity. Known functions and metagenomic pre-
dictions of these microbes suggest the important role of
butyrate and amino acid biosynthesis pathways. The pro-
tective, anti-inflammatory effects of butyrate, which have
previously been observed in MS studies, provide a poten-
tial target for future microbiome interventions intended
to modify disease activity in MS.
Three microbes were associated with subsequent disease
activity in pediatric-onset MS at FDR q < 0.2 and warrant
further functional investigation. These included Blautia
stercoris and Christensenellaceae catabacter, whereby hav-
ing any of these bacteria nearly tripled the hazard of
relapse, and Odoribacter splanchnicus, where having no
copies increased the hazard (four times) of a new
gadolinium-enhancing lesion. In one small case–control
study, higher abundance of Blautia was found among MS
cases compared to controls.33 In line with our findings, a
higher abundance of Blautia and lower abundance of
Odoribacter have been found among individuals with
active lupus disease, another autoimmune disorder, com-
pared to controls.34 Odoribacter has also been found to be
lower among individuals with cystic fibrosis, inflamma-
tory bowel disease, and Crohn’s disease.35–38 The potential
benefits of Odoribacter were largely attributed to its pro-
duction of butyrate, a short-chain fatty acid that can help
maintain gut homeostasis and suppress pro-inflammatory
cytokines.39,40 The presence of Odoribacter was also iden-
tified in our study as associated with lower hazard of
relapse and T2 hyperintense lesions, but results were not
significant after multiple testing correction. In addition to
Odoribacter, four gut microbes were found to be associ-
ated with all three disease activity outcomes before
multiple testing correction. These included three microbes
that may also be beneficial in higher amounts: Butyricicoc-
cus desmolans (another butyrate-producing microbe), an
unidentified species in the genus Lachnospiraceae NKA136
group, and an unidentified species in the family
Ruminococcaceae. In contrast, having any abundance of
an unspecified species belonging to the Coriobacteriales
order more than doubled the hazard of disease activity
outcomes. All of these microbes had consistent effect sizes
across all three MS activity outcomes. Together, these
findings suggest the role of butyrate-producing microbes
in reducing the risk (hazard) of MS relapses and new/en-
larging MRI lesions. This agrees with other studies that
have shown oral administration of butyrate decreased
demyelination in mice, serum butyric acid concentration
was lower among MS cases compared to controls, and
gut butyrate (assessed via metagenomics and stool
metabolites) was reduced among individuals with
relapsing-remitting MS.41–43
Individual microbes are unlikely to work indepen-
dently, and for the first time, unsupervised machine
learning has identified networks (or modules/clusters) of
co-occurring gut microbes associated with disease activity
outcomes in MS. We identified five networks of co-
occurring gut microbes associated with an altered risk of
new gadolinium-enhancing lesions, of which two were
also associated with T2 hyperintense lesions. Across these
five modules, pathways involving aromatic amino acid
biosynthesis were predicted to be enriched. Namely
phenylalanine and tyrosine biosynthesis pathways were
enriched in the M10 module (a module significantly asso-
ciated with a lower hazard of MRI-related outcomes),
while tryptophan was enriched in the M10, M32, and
M33 modules (M32 and 33 were associated with a higher
hazard of MRI-related outcomes). This relationship of
tryptophan with both increased and decreased risk may
relate to differences in the expression of genes in these
microbial modules or their differential catabolism to
bioactive metabolic products, for example, kynurenine.
Tryptophan, specifically, has been identified as a modula-
tor of the central nervous system inflammation and asso-
ciated with MS risk and course.44–46 Interestingly, serum
metabolite studies of MS activity have identified shifts in
aromatic amino acid metabolism among individuals with
worse disease activity.47,48 Our findings suggest that
Figure 6. Five networks of gut microbes were significantly associated with MRI-related multiple sclerosis activity. The long-dashed line indicated
an FDR q cutoff of 0.05 and the small dotted line indicated an FDR q cutoff of 0.2. Significant modules were labeled with their respective module
name. Regression coefficients were scaled to a 0.1-unit increase in module eigengenes because the standard 1-unit increase would represent
nearly the entire range of eigengene values. Regression models were adjusted for sex, age, and disease-modifying therapy use. (A) Adjusted log-
hazard ratios for relapse; (B) adjusted log-hazard ratios for new gadolinium-enhancing lesions on MRI; and (C) adjusted log-hazard ratios for new
or enlarging T2 hyperintense lesions on MRI.
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networks of gut microbes associated with MS activity may
contribute to the concentration of amino acids, specifi-
cally aromatic amino acids that serve as potent CNS and
immunomodulatory signaling molecules.
There are several notable strengths of this study. We
were able to include individuals with MS shortly after dis-
ease onset and follow them prospectively. This captured
clinically relevant relapses and MRI data, the latter of
which are considered highly sensitive and useful when
assessing changes in disease activity over time. Further,
our participants were well characterized and were either
not using a DMT or using drugs with low effectiveness
(in terms of relapse prevention) at baseline. Pediatric-
onset cases are useful because it allows for the examina-
tion of disease processes much closer to biological onset
compared to adults in individuals with very few con-
founding comorbidities.13,49–51 While the gut microbiome
does undergo significant changes in very early childhood,
it is relatively stable in adolescence, with functional capac-
ity similar to adults.52 Because our sample was almost
entirely enrolled as adolescents, this potential source of
variation was limited.
While a pediatric-onset cohort represents a unique
opportunity for studying modifiers of MS, its rarity lim-
ited our sample size and ability to account for other
potential confounders or modifiers, such as study site,
race, ethnicity, body mass index, diet, vitamin D status,
and specific DMTs. The small sample size and large num-
ber of multiple tests also made it particularly challenging
for a result to achieve statistical significance, despite
potential biological significance. Because this study is the
first of its kind, we reported individual ASV findings with
FDR q < 0.2 despite not reaching statistical significance
(FDR q < 0.05). It is possible these may be false positive
findings, and should thus be conservatively interpreted.
They should be considered candidates for future func-
tional studies and hypotheses and replicated in future
work. Another limitation was that all MRI scans were
performed without a centralized or standardized imaging
protocol and the timing of scans was not at predeter-
mined intervals (as part of routine clinical practice).
Finally, metagenomic predictions cannot be interpreted as
true functions or pathways. However, our findings war-
rant further investigation, including microbes that influ-
ence butyrate and amino acid synthesis pathways. We do
not have metabolomic or metagenome data to confirm
predicted findings, which should be the focus of future
work. Additionally, it would be useful for future studies
to collect stool samples repeatedly over time to assess
how changes in gut composition due to treatment, diet,
and other factors might be associated with relapses and
MRI outcomes over time.
In summary, we identified several individual gut
microbes and networks of co-occurring microbes that
were associated with an altered risk of clinical relapse and
activity on brain MRI among pediatric-onset MS patients.
Known functions and metagenomic predictions of these
organisms suggest the roles of butyrate and amino acid
biosynthesis as potential modifiers of MS activity. Further
research is needed to confirm the functional and clinical
implications of these findings, so personalized micro-
biome interventions may be designed to decrease MS
activity.
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Supplementary Table S3. Amplicon sequence variant
(ASV) membership for wgcna modules obtained from
clinical cohort (n = 54).
Supplementary Table S4. Results of recurrent time-to-
event analyses for each module (obtained from MRI
cohort) and MRI outcomes (new gadolinium-enhancing
lesions and new or enlarging T2 lesions). Hazard ratios
(HRs) adjusted for sex, age, and time-varying disease-
modifying therapy use and 95% confidence intervals
(CIs). HRs and 95% CIs are scaled to 0.1-unit increases
in module eigengenes.
Supplementary Table S5. Results of recurrent time-to-
event analyses for each module (obtained from clinical
cohort) and relapse(s). Hazard ratios (HRs) adjusted for
sex, age, and time-varying disease-modifying therapy use
and 95% confidence intervals (CIs). HRs and 95% CIs
are scaled to 0.1-unit increases in module eigengenes.
Supplementary Table S6. Supplementary Table 6.
PICRUSt2 predicted 137 pathways within the M7 module.
Hazard ratios (HRs) and 95% confidence intervals (CIs)
were presented for pathways in at least 20% of samples
for new gadolinium-enhancing lesions. The M7 module
was not associated with relapse or T2 lesions, so pathway
associations were not estimated for these outcomes.
Supplementary Table S7. PICRUSt2 predicted 209 path-
ways within the M10 module. Hazard ratios (HRs) and
95% confidence intervals (CIs) were presented for path-
ways in at least 20% of samples for new gadolinium-en-
hancing lesions. The M10 module was not associated with
relapse or T2 lesions, so pathway associations were not
estimated for these outcomes.
Supplementary Table S8. PICRUSt2 predicted 122 path-
ways within the M11 module. Hazard ratios (HRs) and
95% confidence intervals (CIs) were presented for path-
ways in at least 20% of samples for new gadolinium-en-
hancing lesions. The M11 module was not associated with
relapse or T2 lesions, so pathway associations were not
estimated for these outcomes.
Supplementary Table S9. PICRUSt2 predicted 168 path-
ways within the M32 module. Hazard ratios (HRs) and
95% confidence intervals (CIs) were presented for path-
ways in at least 20% of samples for MRI outcomes. The
M32 module was not associated with relapse, so pathway
associations with relapse were not estimated. Results are
sorted by gadolinium-enhancing FDR q and HR and then
T2 lesion FDR q and HR.
Supplementary Table S10. PICRUSt2 predicted 131 path-
ways within the M33 module. Hazard ratios (HRs) and
95% confidence intervals (CIs) were presented for path-
ways in at least 20% of samples. The M33 module was
not associated with relapse, so pathway associations with
relapse were not estimated. Results are sorted by gadolin-
ium-enhancing FDR q and HR and then T2 lesion FDR q
and HR.
Supplementary Figure S1. Total proportion of abundance
of microbes (by class) according to baseline disease-modi-
fying therapy status. The proportion of individuals ASVs
belonging to a particular taxonomic class did not signifi-
cantly differ by baseline DMT use categories (none, glati-
ramer acetate, interferon beta, or other DMT) except for
Melainabacteria (p = 0.0002) and Verrucomicrobiae
(p = 0.049). p-values determined from F-test.
Supplementary Figure S2. Weighted genetic correlation
network analysis identified 33 modules of co-occurring
microbes for the MRI cohort and 27 modules for the
clinical cohort. (A and B) Bacterial taxa dendrogram and
module names (colors) for MRI and clinical cohorts,
respectively. Each node was an ASV. Taxa that co-occur
were positioned closer together and the module for which
an ASV was a member was plotted in a vertical band
below. (C and D) Clustering of module eigenvalues for
MRI and clinical cohorts, respectively, with corresponding
names (number and color).
Supplementary Figure S3. Pathways predicted to be asso-
ciated with significant gut microbial modules from
PICRUSt2. Each row was a MetaCyc pathway that was
associated with a pediatric-onset multiple sclerosis out-
come at p < 0.05 in at least one of the five significant
microbial modules (M7, 10, 22, 32, 33). Colors indicated
the magnitude of hazard ratios, adjusted for sex, age, and
disease-modifying therapy use, which represented the
association between a pathway and pediatric-onset MS
activity outcome, per module (columns). Hazard ratios
were only estimated for disease activity outcomes previ-
ously identified as associated with a respective module.
Gray indicated the module-specific pathway-outcome
association had p ≥ 0.05. Hazard ratios were estimated
for pathways present in at least 20% of the respective
cohort and module. No pathways within the M7 or M11
modules were significant, so were not shown. Abbrevia-
tions: Gad, gadolinium; MS, multiple sclerosis.
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